Osteoarthritis (OA) affects approximately 20% of Australians and costs billions each year in joint replacements. Therapies that halt joint destruction in OA are urgently needed. We hypothesise that the little-known gene, vanin -3, is a key regulator of OA disease pathways. Our project will map vanin-3 in the joint and reveal how much vanin-3 contributes to joint destruction in mice. We expect to find a link between vanin-3 and metabolic disorders and identify new targets for therapy.
DICKENS - A Randomised Controlled Trial Of DIaCerein To Treat KneE Osteoarthritis With EffusioN-Synovitis
Funder
National Health and Medical Research Council
Funding Amount
$1,327,836.00
Summary
Knee osteoarthritis (OA) is common, but the current treatments are poor. Almost 60% of people with knee OA have joint inflammation. Patients with inflammation are more likely to experience joint pain and rapid joint destruction. We propose that treating patients with inflammatory knee OA with the anti-inflammatory drug, diacerein, will reduce pain and joint damage.
ARC, A Newly Identified Regulator Of Chondrocyte Differentiation And Death, Is A Novel Therapeutic Target For OA
Funder
National Health and Medical Research Council
Funding Amount
$763,983.00
Summary
We have identified a critical regulator of the survival and normal metabolism of the cells in articular cartilage. Loss of this molecule is an early event in joint injury that leads to osteoarthritis (OA). The current proposal will determine the mechanisms whereby this protein functions to protect cartilage breakdown in OA, how its levels in chondrocytes are regulated in both healthy and diseased conditions, and at what stages of disease increasing its expression protects against OA progression.
Understanding The Development Of Autoimmunity In Response To Citrullinated Peptide Antigen Presentation To T Cells In Rheumatoid Arthritis
Funder
National Health and Medical Research Council
Funding Amount
$1,181,793.00
Summary
Rheumatoid arthritis (RA) is a systemic autoimmune disease predominantly affecting synovial joints, in 1% of adults worldwide. HLA-class II genes underlie the major genetic susceptibility to RA. The programme of work brings together 7 investigators from 3 countries to determine how autoimmunity develops to self antigens in individuals at genetic risk of RA and why resistance alleles are protective against RA, in Caucasian, Asian and North American Native populations. We will provide a molecular
Targeting Autophagy As A Means Of Control Of Cytokine Production In SLE
Funder
National Health and Medical Research Council
Funding Amount
$616,518.00
Summary
Systemic lupus erythematosus (SLE, or lupus) is a common immune disease that causes organ damage and loss of life, chiefly affecting young women. There is no cure for SLE. We have discovered that a natural process called 'autophagy' could be a way to limit inflammation during SLE. In this project we will discover whether this could lead to a new way to treat this disease.
A Randomised Trial Of Zoledronic Acid For Osteoarthritis Of The Knee
Funder
National Health and Medical Research Council
Funding Amount
$989,238.00
Summary
Osteoarthritis (OA) is the most common form of arthritis and is increasing markedly due to an ageing population. Despite its large disease burden, there are currently no approved disease-modifying drugs available which modify structural progression of OA. The aim of this study is to compare zoledronic acid treatment to placebo on knee structural change and knee pain over two years. It is hypothesised that zoledronic acid will reduce cartilage loss, knee pain, and bone marrow lesion size.
A Randomised Controlled Trial To Evaluate The Effectiveness Of Zoledronate Therapy In Osteonecrosis Of The Hip.
Funder
National Health and Medical Research Council
Funding Amount
$535,441.00
Summary
Osteonecrosis of the hip is an important cause of musculoskeletal disability and finding therapeuticsolutions has proven to be challenging. A wide range of surgical treatments with variable success rates ahve been proposed for the treatment. Non-surgical treatment options are limited and usually result in a poor prognosis. This novel clinical trial research will study the protective value of a bisphosphonate in patients with osteonecrosis of the hip and evaluate the cost-effectiveness.
Web Based Study Of Risk Factors For Pain Exacerbation In Knee Osteoarthritis
Funder
National Health and Medical Research Council
Funding Amount
$408,501.00
Summary
While much is known about the risk factors for radiographic knee OA, the risk factors for symptoms emanating from joints affected by OA remain unclear. Identifying modifiable methods for alleviating pain and or avoiding risk factors for exacerbations of pain could have tremendous public health importance. In the proposed study we will use the Internet to facilitate data collection to test a set of risk factors for knee pain fluctuation among subjects with symptomatic radiographic knee OA.
Towards A Rational Strategy For Osteoarthritis Therapy
Funder
National Health and Medical Research Council
Funding Amount
$945,993.00
Summary
Osteoarthritis is the most common form of arthritis, causing disability and chronic pain, for which there are no adequate treatments. Our laboratory has shown that a particular protein is involved in inflammatory arthritis and pain. Blocking this protein in patients with rheumatoid arthritis is showing success. In this project we will carry out some preclinical studies to determine whether blockade of this protein may also be a therapeutic target for osteoarthritis pain and disease.
Sclerostin Is A Key Regulator Of Wnt Signalling In Bone And Cartilage Pathology In Osteoarthritis
Funder
National Health and Medical Research Council
Funding Amount
$590,945.00
Summary
Osteoarthritis (OA) is the most widespread bone and joint problem in Australia with has enormous social and economic consequences. We have identified Sclerostin (SOST) as a key regulator of the signalling pathway that drives the increase in production of bone and the erosion of cartilage in joints that are the hallmark of OA. The aims of the present project are to determine the effect altering SOST activity on the initiation and progression of OA.